Third Harmonic Bio Inc reports results for the quarter ended March 31 - Earnings Summary

• Third Harmonic Bio Inc THRD.OQ reported a quarterly adjusted loss of 35 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -20 cents. The mean expectation of four analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -30 cents to -28 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Third Harmonic Bio Inc's reported EPS for the quarter was a loss of 35 cents​.

• The company reported a quarterly loss of $15.83 million.

• Third Harmonic Bio Inc shares had risen by 48.7% this quarter and lost 49.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Third Harmonic Bio Inc is $5.23

This summary was machine generated from LSEG data May 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)